These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 25946693)

  • 41. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy.
    Izumi T; Koizumi H; Maruko I; Takahashi Y; Sonoda S; Sakamoto T; Iida T
    Br J Ophthalmol; 2017 Apr; 101(4):433-437. PubMed ID: 27388248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
    Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA
    Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.
    Jirarattanasopa P; Ooto S; Tsujikawa A; Yamashiro K; Hangai M; Hirata M; Matsumoto A; Yoshimura N
    Ophthalmology; 2012 Aug; 119(8):1666-78. PubMed ID: 22521082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
    Goto S; Gomi F; Ueno C; Nishida K
    Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
    Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
    Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
    Peiretti E; Caminiti G; Serra R; Querques L; Pertile R; Querques G
    Retina; 2018 Aug; 38(8):1526-1532. PubMed ID: 28699928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion.
    Tsuiki E; Suzuma K; Ueki R; Maekawa Y; Kitaoka T
    Am J Ophthalmol; 2013 Sep; 156(3):543-547.e1. PubMed ID: 23688711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.
    Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S
    Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy.
    Yang HS; Kang TG; Park H; Heo JS; Park J; Lee KS; Choi S
    PLoS One; 2020; 15(1):e0227718. PubMed ID: 31929582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy.
    Hamzah F; Shinojima A; Mori R; Yuzawa M
    BMC Ophthalmol; 2014 Nov; 14():145. PubMed ID: 25421855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy.
    Kinoshita T; Mitamura Y; Mori T; Akaiwa K; Semba K; Egawa M; Mori J; Sonoda S; Sakamoto T
    PLoS One; 2016; 11(9):e0163104. PubMed ID: 27636093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
    Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
    Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
    Park W; Kim M; Kim RY; Park YH
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
    Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee JH; Lee WK
    Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.